TuHURA Biosciences (NASDAQ:HURA) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

TuHURA Biosciences (NASDAQ:HURA) issued its earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01), Zacks reports.

TuHURA Biosciences Stock Down 9.5%

NASDAQ:HURA opened at $1.62 on Thursday. The firm’s fifty day simple moving average is $1.36 and its 200 day simple moving average is $1.64. The stock has a market cap of $98.37 million, a P/E ratio of -2.57 and a beta of -0.32. TuHURA Biosciences has a twelve month low of $0.41 and a twelve month high of $4.44.

Institutional Investors Weigh In On TuHURA Biosciences

Several institutional investors and hedge funds have recently modified their holdings of HURA. Geode Capital Management LLC boosted its stake in shares of TuHURA Biosciences by 111.4% during the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock valued at $1,300,000 after purchasing an additional 307,260 shares in the last quarter. Deutsche Bank AG lifted its holdings in TuHURA Biosciences by 209.8% in the fourth quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock worth $61,000 after buying an additional 54,051 shares during the period. New York State Common Retirement Fund bought a new stake in TuHURA Biosciences during the 2nd quarter valued at approximately $97,000. Goldman Sachs Group Inc. bought a new stake in TuHURA Biosciences during the 4th quarter valued at approximately $30,000. Finally, Marshall Wace LLP purchased a new position in shares of TuHURA Biosciences during the 2nd quarter worth approximately $79,000. 0.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on HURA shares. Wall Street Zen raised shares of TuHURA Biosciences from a “sell” rating to a “hold” rating in a report on Monday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Thursday, January 22nd. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of TuHURA Biosciences in a report on Tuesday, February 3rd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $9.00.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.